参考文献/References:
[1] HIDALGO M,AMANT F,BIANKIN A V,BUDINSK E,BYRNE A T,CALDAS C,et al.Patient-derived xenograft models:an emerging platform for translational cancer research[J].Cancer Discov,2014,4(9):998-1013.
[2] CASSIDY J W,CALDAS C,BRUNA A.Maintaining tumour heterogeneity in patient-derived tumour xenografts[J].Cancer Res,2015,75(15):2963-2968.
[3] SIA D,MOEINI A,LABGAA I,VILLANUEVA A.The future of patient-derived tumor xenografts in cancer treatment[J].Pharmacogenomics,2015,16(14):1671-1683.
[4] LI K J,HUANG H,GAO R.Research progress of patient-derived xenografts in precision cancer medicine[J].Chin J Comp Med,2017,27(1):91-98.
李克娟,黄昊,高苒.人源肿瘤异种移植模型在精准肿瘤医学中的研究进展[J].中国比较医学杂志,2017,27(1):91-98.
[5] FABIAN I D,ONADIM Z,KARAA E,DUNCAN C,CHOWDHURY T,SCHEIMBERG I,et al.The management of retinoblastoma[J].Oncogene,2018,37(12):1551-1560.
[6] BHAVNA C,GAUTAM L,SUSHMITA P.Recent advances in management of retinoblastoma:A review[J].World J Ophthalmol,2015,5(1):31-35.
[7] CASSOUX N,THULEAU A,ASSAYAG F,AERTS I,DECAUDIN D.Establishment of an orthotopic xenograft mice model of retinoblastoma suitable for preclinical testing[J].Ocul Oncol Pathol,2015,1(3):200-206.
[8] AERTS I,LEURAUD P,BLAIS J,POULIQUEN AL,MAILLARD P,HOUDAYER C,et al.In vivo efficacy of photodynamic therapy in three new xenograft models of human retinoblastoma[J].Photodiagnosis Photodyn Ther,2010,7(4):275-283.
[9] ASSAYAG F,NICOLAS A,VACHER S,DEHAINAULT C,BIECHE I,MESEURE D,et al.Combination of carboplatin and bevacizumab is an efficient therapeutic approach in retinoblastoma patient-derived xenografts[J].Invest Ophthalmol Vis Sci,2016,57(11):4916-4926.
[10] LEMAITRE S,POYER F,MARCO S,FRNEAUX P,DOZ F,AERTS I,et al.Looking for the most suitable orthotopic retinoblastoma mouse model in order to characterize the tumoral development[J].Invest Ophthalmol Vis Sci,2017,58(7):3055-3064.
[11] SPAGNOLO F,CALTABIANO G,QUEIROLO P.Uveal melanoma[J].Cancer Treatment Reviews,2012,38(5):549-553.
[12] CARITA G,DECAUDIN D.Uveal melanoma patient-derived xenografts[J].Ocul Oncol Pathol,2015,1(3):161-169.
[13] NMATI F,SASTRE-GARAU X,LAURENT C,COUTURIER J,MARIANI P,DESJARDINS L,et al.Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors[J].Clin Cancer Res,2010,16(8):2352-2362.
[14] LAURENT C,GENTIEN D,PIPERNO-NEUMANN S,NMATI F,NICOLAS A,TESSON B,et al.Patient-derived xenografts recapitulate molecular features of human uveal melanomas[J].Mol Oncol,2013,7(3):625-636.
[15] NMATI F,MONTRION C D,LANG G,KRAUS-BERTHIER L,CARITA G,SASTRE-GARAU X,et al.Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived Xenografts[J].PLoS One,2014,9(1):e80836.
[16] PAL B P,GARGE S,KHETAN V.Choroidal melanoma:a short review with an Indian perspective[J].Oman J Ophthalmol,2017,10(3):135-144.
[17] LEMAITRE S,NEMATI F,THULEAU A,LABIOD D,RODRIGUES M,PLATER L D,et al.Preclinical scheduling for metastatic ocular melanoma treatment by using a xenograft model approach[J].Acta Ophthalmol,2014,92(s253):0.
[18] VORA G K,DEMIRCI H,MARR B,MRUTHYUNJAYA P.Advances in the management of conjunctival melanoma[J].Sur Ophthalmol,2017,62(1):26-42.